Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Circulating cell-free DNA (cfDNA) is a large molecule that plays a central role in the pathogenesis of SLE. It is the target antigen of autoantibodies and the main component of immune complexes. Due to the large differences in the content of cfDNA detected in different studies, cfDNA cannot be used as a strong diagnostic basis for SLE at present. As an active component of cfDNA, the correlation between double-stranded DNA (dsDNA) and SLE has not been fully studied. The detection of dsDNA may provide a more accurate diagnosis and treatment basis for SLE, and the in-depth study of SLE patients is helpful to further understand the pathogenesis of SLE. Blood samples were collected from 173 SLE patients and 2970 healthy controls. The concentration of serum dsDNA was determined by fluorescence quantitative method. Propensity score matching (PSM) method was used to match 444 healthy controls and 148 SLE patients according to age and gender. Serum dsDNA levels were compared between SLE patients and matched healthy controls. At the same time, blood exosomes were extracted to explore the correlation between serum dsDNA and exosome dsDNA. As demonstrated herein, serum dsDNA levels in SLE patients were shown to be considerably higher than in healthy controls. Meanwhile, In SLE patients, serum dsDNA level was correlated with season and other clinical indicators, but not with temperature and ultraviolet. Additionally, a statistically significant connection between serum and exosome dsDNA was discovered. We also found that the gene encoding the dsDNA receptor was upregulated. The presented data suggest that detection of dsDNA is promising as a rapid and simple tool for assessing disease progression in SLE, which can help physicians and patients in disease management. The mechanism of elevated dsDNA in SLE patients requires more research.

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.70102DOI Listing

Publication Analysis

Top Keywords

sle patients
28
serum dsdna
20
healthy controls
16
sle
13
dsdna
12
correlation double-stranded
8
double-stranded dna
8
pathogenesis sle
8
basis sle
8
dsdna sle
8

Similar Publications

Case Report: Sequential treatment with rituximab and belimumab in a pediatric patient of type 1 diabetes mellitus complicated with systemic lupus erythematosus.

Front Pediatr

August 2025

Department of Rheumatology and Immunology, Tianjin Children's Hospital (Children's Hospital, Tianjin University), Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin, China.

Type 1 diabetes mellitus (T1DM) and systemic lupus erythematosus (SLE) are both autoimmune diseases influenced by multiple genetic and environmental factors, but rarely coexist. This case describes a 13-year-old girl with early onset of T1DM who was diagnosed with SLE 12 years later, highlighting diagnostic and therapeutic challenges, particularly in distinguishing kidney involvement and management without exacerbating hyperglycemia. The patient presented with edema of the eyelids and lower limbs.

View Article and Find Full Text PDF

Neutrophilic urticarial dermatosis (NUD) is a rare condition that clinically resembles urticaria but is distinguished histopathologically. Given the overlap of clinical and histopathologic features between NUD, urticaria, and urticarial vasculitis (UV), distinguishing between these diagnoses is crucial, as their treatments differ significantly. A 47-year-old woman with systemic lupus erythematosus (SLE) presented with a mildly pruritic, burning rash for one week.

View Article and Find Full Text PDF

The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months.

View Article and Find Full Text PDF

Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.

J Pharmacol Exp Ther

July 2025

Department of Pharmacy Practice, Parul Institute of Pharmacy & Research, Parul University, Limda, Waghodia, Vadodara, Gujarat, India. Electronic address:

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by widespread inflammation and immune system dysregulation. Recent research suggests that the gut microbiota may play a role in the development of SLE by modulating immune system responses, affecting cytokine production, and altering the activity of T and B cells lymphocytes. As a result, there is a growing interest in microbiota-targeted therapies, including probiotics, dietary changes, and fecal microbiota transplantation.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.

View Article and Find Full Text PDF